The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi, AbbVie) for a third indication — treatment of moderately to severely active Crohn’s disease in adults — making it the first specific anti-interleukin 23 (IL-23) monoclonal antibody indicated for Crohn’s disease.
Are you looking for or in search of FDA approved “sacituzumab govitecan-hziy for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of sacituzumab govitecan-hziy injection, get in touch with our healthcare professional.
This medication is used to treat plaque psoriasis and psoriatic arthritis. It is also used to treat a certain bowel condition called Crohn’s disease. Risankizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.
Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. Risankizumab-rzaa is in a class of